PQJS380: a novel lead compound to induce apoptosis in acute lymphoblastic leukemia cells.

Hallmarks of cancer: the next generation. Cell (2011) 140.01

Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science (2001) 23.42

An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40

The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol (2008) 20.89

The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell (2002) 13.92

Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30

BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell (2001) 9.33

Acute lymphoblastic leukaemia. Lancet (2008) 8.54

Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene (2001) 4.70

Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev (2003) 4.00

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood (2001) 3.93

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood (2003) 3.37

Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer (2002) 3.18

Acute lymphoblastic leukemia. N Engl J Med (1998) 3.15

Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood (2000) 3.13

Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene (2003) 2.59

Melanoma epidemiology and trends. Clin Dermatol (2008) 2.57

Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp Cell Res (2003) 1.88

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood (2005) 1.83

Focus on acute leukemias. Cancer Cell (2002) 1.67

Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol (2003) 1.54

Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol (2008) 1.50

The role of MLL in hematopoiesis and leukemia. Curr Opin Hematol (2002) 1.42

Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene (2002) 1.41

BimS-induced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteins. J Cell Biol (2007) 1.33

Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol (2002) 1.26

Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res (2009) 1.23

Bcl-w forms complexes with Bax and Bak, and elevated ratios of Bax/Bcl-w and Bak/Bcl-w correspond to spermatogonial and spermatocyte apoptosis in the testis. Mol Endocrinol (2000) 1.17

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood (2006) 1.04

Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia. Haematologica (2007) 1.04

Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. Mol Pharmacol (2009) 1.01

Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia (2000) 1.00

A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia. Cancer Gene Ther (2012) 0.99

Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood (2007) 0.96

Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clin Cancer Res (2007) 0.95

Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression. Mol Cancer (2010) 0.93

Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology. Jpn J Clin Oncol (2008) 0.91

Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity. Oncogene (2005) 0.91

TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches. Curr Opin Hematol (2002) 0.91

Activity of triptolide against human mast cells harboring the kinase domain mutant KIT. Cancer Sci (2009) 0.78